Centogene receives delisting notice from nasdaq

Cambridge, mass. and rostock, germany and berlin, aug. 07, 2024 (globe newswire) -- centogene n.v., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the nasdaq stock market llc (“nasdaq”) indicating that the nasdaq hearings panel has determined to delist centogene's common stock from nasdaq. the notice indicates that centogene (the “company”) remains noncompliant with nasdaq listing rule 5450(b)(2)(c), which requires a minimum usd 15 million market value of publicly held shares.
CNTG Ratings Summary
CNTG Quant Ranking